CliffBio
small molecule

ONFI

CLOBAZAM

Loss of exclusivity—loss of exclusivity
CompanyLundbeck →See this company's full patent-cliff portfolio

Drug detail

Brand nameONFI
Active ingredientCLOBAZAM
Strength10MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2011
Marketing statusRX

More from Lundbeck

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.